以伊布替尼为基础的联合方案治疗复发/难治性中枢神经系统淋巴瘤的1b期试验
这项1b期试验探索伊布替尼(每日560或840 mg)序贯联合大剂量甲氨蝶呤(HD-MTX)和利妥昔单抗治疗中枢神经系统淋巴瘤。联合方案耐受性可接受,无5级事件、3例4级事件,未观察到剂量限制性毒性;15例中12例(80%)出现临床缓解,持续肿瘤缓解与脑脊液循环肿瘤DNA清除相关。
要点
- 伊布替尼联合HD-MTX和利妥昔单抗耐受性可接受,无5级事件、3例4级事件,未观察到剂量限制性毒性。
- 15例中12例(80%)出现临床缓解,11例完成4周期联合治疗后进入伊布替尼维持。
- 持续肿瘤缓解与脑脊液循环肿瘤DNA清除相关。
核心结论
- 伊布替尼联合HD-MTX和利妥昔单抗耐受性可接受,15例中12例(80%)出现临床缓解,持续肿瘤缓解与脑脊液循环肿瘤DNA清除相关。
研究设计与样本
- 1b期临床试验,探索伊布替尼(每日560或840 mg)序贯联合HD-MTX和利妥昔单抗治疗中枢神经系统淋巴瘤患者。
- HD-MTX按3.5 g/m2每2周给药,共8剂(4周期;1周期=28天)。
- 伊布替尼在HD-MTX输注日暂停,于HD-MTX输注后5天或HD-MTX清除后恢复。
- 诱导治疗完成后持续单药每日伊布替尼直至疾病进展、不可耐受毒性或死亡。
- 探索治疗前和治疗中脑脊液循环肿瘤DNA二代测序;试验注册号NCT02315326。
主要发现
- 联合方案耐受性可接受,无5级事件、3例4级事件,未观察到剂量限制性毒性。
- 15例中11例完成4周期伊布替尼/HD-MTX/利妥昔单抗联合治疗后进入伊布替尼维持。
- 15例中12例(80%)出现临床缓解。
- 持续肿瘤缓解与脑脊液循环肿瘤DNA清除相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK) and has shown single-agent activity in recurrent/refractory central nervous system (CNS) lymphoma. Clinical responses are often transient or incomplete, suggesting a need for a combination therapy approach. We conducted a phase 1b clinical trial to explore the sequential combination of ibrutinib (560 or 840 mg daily dosing) with high-dose methotrexate (HD-MTX) and rituximab in patients with CNS lymphoma (CNSL). HD-MTX was given at 3.5 g/m2 every 2 weeks for a total of 8 doses (4 cycles; 1 cycle = 28 days). Ibrutinib was held on days of HD-MTX infusion and resumed 5 days after HD-MTX infusion or after HD-MTX clearance. Single-agent daily ibrutinib was administered continuously after completion of induction therapy until disease progression, intolerable toxicity, or death. We also explored next-generation sequencing of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) before and during treatment. The combination of ibrutinib, HD-MTX, and rituximab was tolerated with an acceptable safety profile (no grade 5 events, 3 grade 4 events). No dose-limiting toxicity was observed. Eleven of 15 patients proceeded to maintenance ibrutinib after completing 4 cycles of the ibrutinib/HD-MTX/rituximab combination. Clinical responses occurred in 12 of 15 patients (80%). Sustained tumor responses were associated with clearance of ctDNA from the CSF. This trial was registered at www.clinicaltrials.gov as #NCT02315326.
引用
- Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2018. PMID: 30567753. doi:10.1182/blood-2018-09-875732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。